Researchers from the George Institute for Global Health received a $5.5 million project grant from the National Health and Medical Research Council for research into kidney disease. With additional support provided by Bayer, the initiative aims to prevent cardiovascular disease in people who have advanced kidney disease.

According to a press release, the new international trial will evaluate whether a low dose of blood-thinning medication found to be beneficial in patients with CVD will also safely reduce the number of CV events in patients with chronic kidney disease.

The release noted approximately 2,000 patients with CKD in Australia, New Zealand, Malaysia, India, China, Canada, and the United Kingdom would receive a low dose of the blood-thinning medication in the 5-year randomized trial, making it the first and largest trial evaluating blood-thinning medicines for people with CKD. The George Institute will lead the new research and supported by Kidney Health Australia, Bayer, and researchers from around the world.

Chronic Kidney Disease

Patients with chronic kidney disease are missing out on life-saving treatments. We hope this trial will help millions of people around the world by providing them with a medication that will prevent them from dying of a heart attack or suffering a stroke.

”Sunil Badve, lead researcher and senior research fellow and associate professor of medicine at the George Institute for Global Health, UNSW Sydney, said in the release. “It’s an exciting opportunity to address this unmet need and hopefully deliver a treatment that will save lives and also save money as chronic kidney disease is a complex condition to manage.

It’s an exciting opportunity to address this unmet need and hopefully deliver a treatment that will save lives and also save money as chronic kidney disease is a very complex condition to manage,” added Associate Professor Badve, who is also a nephrologist at St George Hospital, Sydney.

Around 2000 patients with CKD in Australia, New Zealand, Malaysia, India, China, Canada, and the UK will take part in the five-year randomized trial and receive the blood thinning medication at a low dose to try to avoid associated side effects.

Dr. Eduardo Pimenta, Head of Medical Affairs, Bayer ANZ, said: “Bayer is proud to partner with The George Institute and Kidney Health Australia to address a significant gap in the evidence and management of cardiovascular disease in people with end-stage kidney disease.

Collaborations such as this underscore our commitment to facilitating ground-breaking research to improve patient outcomes in the future. ”Dr Shilpa Jesudason, Clinical Director of Kidney Health Australia, which is working with The George Institute in regards to patient involvement, said: "As the peak organization for patients living with kidney disease, their families and community, Kidney Health Australia is excited to be partnering with The George Institute to bring the consumer voice to this study.

Patient and consumer engagement at all stages of research design, trial implementation, and knowledge dissemination adds enormous value to the quality, conduct, and relevance of clinical trials.